STAT3 and lung cancer: Previous studies suggested that IL-37 could inhibit the activation of the NF-κB and IL-6/STAT3 signaling pathway and suppressed the occurrence of the inflammatory response in Myasthenia Gravis (MG) by affecting Tfh and B cells, and in lung cancer by affecting A549 cells [46, 51].